A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.

Clinical Therapeutics
Xiaoyuan GongJianxiang Wang

Abstract

Dasatinib is a second-generation tyrosine kinase inhibitor with higher central nervous system (CNS) penetration compared with imatinib and nilotinib in in vitro studies. However, limited clinical data are available regarding the dosage and CNS penetration of dasatinib. The purpose of this study was to investigate the actual ability of dasatinib to cross the blood-brain barrier in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Plasma and cerebrospinal fluid (CSF) samples collected from Ph+ ALL patients treated with dasatinib were analyzed by using an LC-MS/MS assay. Orally administered dasatinib 100 mg once daily was well absorbed by the patient but penetrated poorly into the CSF. The use of a higher drug dosage (140 mg/d) may increase systemic drug exposure and enhance the penetration of dasatinib into the CSF. Based on this study, the use of a higher dosage of dasatinib (140 mg/d) is recommended in patients at high risk of CNS relapse or patients who need treatment for CNS leukemia. ClinicalTrials.gov identifier: NCT02523976.

References

Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Jun 13, 2015·Blood·Dae-Young KimUNKNOWN Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology
Mar 1, 2017·Current Hematologic Malignancy Reports·Lalit Saini, Joseph Brandwein
Feb 15, 2018·The Journal of Pharmacology and Experimental Therapeutics·Janice K LaramyWilliam F Elmquist
May 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William B SlaytonStephen P Hunger
Jan 25, 2019·Current Treatment Options in Oncology·Iman Abou DalleFarhad Ravandi
Dec 1, 2019·International Journal of Cancer. Journal International Du Cancer·Jia-Bao HeQi-Fa Liu
Mar 1, 2020·Clinical Pharmacokinetics·Dominique LevêqueShanti Natarajan-Amé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.